Lite Strategy (LITS) Net Cash Flow (2010 - 2026)
Lite Strategy (LITS) posted quarterly Net Cash Flow of -$1.2 million for Q1 2026, up 62.84% year-over-year from -$745514.7 in Q1 2025, and up 10.41% quarter-over-quarter from -$1.4 million in Q4 2025.
Lite Strategy (LITS) Net Cash Flow (2010 - 2026) Analysis & Trends
Lite Strategy's Net Cash Flow history runs 17 years deep, the most recent figure standing at -$1.2 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 62.84% year-over-year to -$1.2 million; the TTM figure through Mar 2026 stood at -$12.9 million (down 171.41% YoY), while the FY2025 annual figure was $14.3 million, up 208.37% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$1.2 million, up from -$1.4 million in the prior quarter.
- The five-year high for Net Cash Flow was $16.8 million in Q4 2024, with the low at -$13.5 million in Q3 2023.
- The 5-year median for Net Cash Flow is -$1.4 million (2025), against an average of -$294529.4.
- The sharpest annual moves came in 2023 and 2024: Net Cash Flow tumbled 1145.08% in 2023, then soared 831.58% in 2024.
- Lite Strategy's Net Cash Flow stood at -$3.7 million in 2022, then soared by 148.23% to $1.8 million in 2023, then jumped by 831.58% to $16.8 million in 2024, then plunged by 108.07% to -$1.4 million in 2025, then increased by 10.41% to -$1.2 million in 2026.
- Business Quant data shows LITS's Net Cash Flow at -$1.2 million in Q1 2026, -$1.4 million in Q4 2025, and -$7.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Lite Strategy | 35.71 Mn | 28.17 Mn | - | -1.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.21 Mn |
| Mar 31, 2026 | -1.21 Mn |
| Dec 31, 2025 | -1.36 Mn |
| Dec 31, 2025 | -1.36 Mn |
| Sep 30, 2025 | -7.90 Mn |
| Sep 30, 2025 | -7.90 Mn |
| Jun 30, 2025 | -2.46 Mn |
| Jun 30, 2025 | -2.46 Mn |
| Mar 31, 2025 | -3.27 Mn |
| Mar 31, 2025 | -3.27 Mn |
| Dec 31, 2024 | 16.79 Mn |
| Dec 31, 2024 | 16.79 Mn |
| Sep 30, 2024 | 3.25 Mn |
| Sep 30, 2024 | 3.25 Mn |
| Jun 30, 2024 | 1.34 Mn |
| Jun 30, 2024 | 1.34 Mn |
| Mar 31, 2024 | -2.81 Mn |
| Mar 31, 2024 | -2.81 Mn |
| Dec 31, 2023 | 1.80 Mn |
| Dec 31, 2023 | 1.80 Mn |